

# Global Peptide Antibiotics Market & Clinical Pipeline Insight 2023

<https://marketpublishers.com/r/G1C50B297D1EN.html>

Date: June 2017

Pages: 140

Price: US\$ 2,000.00 (Single User License)

ID: G1C50B297D1EN

## Abstracts

**Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.**

“Global Peptide Antibiotics Market & Clinical Pipeline Insight 2023” report gives comprehensive insight on clinical and non-clinical parameters involved in the development and commercialization of global peptide antibiotics market. As per report findings, peptide antibiotics are expected to emerge as new growth frontier for the various stake holders involved in the research and development of antibiotics. Currently, there are 6 peptide antibiotics commercially available in the market and 24 peptide antibiotics are in clinical pipeline. With the era of “classical antibiotics” coming to an end with problems like heavy resistance to conventional antibiotics, the new era of peptide antibiotics is on its way to revolutionize the antibiotics segment. The peptide antibiotics are at the apex of new generation medications which are sure to storm the markets in the coming years.

Currently, antibiotics are the major source of revenues for the major pharmaceutical players. The demand for antibiotics is rapidly rising with many companies heavily investing in the growth of the antibiotics market. The global antibiotic demand is expected to surpass US\$ 40 Billion by 2023 from less than US\$ 30 Billion in 2017. However, multiple cases of antibiotic resistance have caused a concern in the healthcare industries which in turn is a major threat to the pharmaceuticals companies as it might cost them a considerable part of their revenues and profit. This situation has led to intensive research and development in the field of peptide antibiotics. The idea of a peptide antibiotic provides a one stop solution to the above issue. The inability of organisms to develop resistance against the newly developed peptide antibiotic, its increased efficacy, high specificity, decreased drug interaction, low toxicity, biological diversity and direct attacking property has made it an efficient product that could have

tremendous impact in revolutionizing the new era of antibiotics.

US dominate the global production and commercialization of peptide antibiotics followed by Europe. Companies like Theravance and Vicuron Pharmaceuticals are the major American companies largely dedicated in the development of peptide antibiotics. Their dominance in the global antibiotics market is estimated to remain stable over the next years. However, developing nations like China and India are believed to contribute significantly to the overall growth of the antibiotics market in the near future with their incessant population and demand for antibiotics growing at an alarming rate annually. The success of peptide vaccines would greatly impact the global antibiotics scenario with the conventional antibiotics being replaced. However the rate at which this would happen is still uncertain.

FDA has approved vanomycin and bacitracin as peptide antibiotics, largely used for the treatment of bacterial infection. Recent innovations and advancement in the peptide antibiotics segment has further opened up opportunities in the oncology field with researchers trying to find antibiotics against carcinogenic bacterial infections. Increase in antibiotic resistance, emergence of large scale infections and new opportunities in the oncology segment have led to increased investment in the peptide antibiotics market which seems to be the best alternative healthcare researchers have. These have altogether been the major driving factors in the development of peptide antibiotics.

With the advancement in scientific knowledge and increased research globally, the peptide antibiotics segment is bound to rise. Collaborations between major pharmaceuticals giants fuelled by increased investment and support from various government and foundations have positively impacted the growth in the peptide vaccine market. It is evident that antibiotic resistance would severely impact the antibiotics market, thus the dire need for an alternative. This particular need can successfully be fulfilled by the emergence of peptide antibiotics which would rapidly become an alternative or the most possible solution in situations where the conventional antibiotics fail. Thus it could fairly be concluded that the peptide antibiotics are the new plethora of opportunities with the potential of generating immense revenue in the future.

## Contents

### **1. PEPTIDE ANTIBIOTICS - A NEW ERA FOR ANTIBIOTICS**

- 1.1 Introduction
- 1.2 Systemization of Peptide Antibiotics & Drugs
  - 1.2.1 Non-Ribosomally Synthesized Peptide Antibiotics
  - 1.2.2 Ribosomal Synthesized Peptide Antibiotics

### **2. MECHANISM & PRODUCTION OF PEPTIDE ANTIBIOTICS**

- 2.1 Approach of Peptide Antibiotics on Bacterial Surface
- 2.2 Creational Process of Peptide Antibiotics

### **3. IDENTIFICATION OF HUMAN ANTIMICROBIAL PEPTIDES**

- 3.1 Human Defensins
- 3.2 Human Cathelicidins
- 3.3 Antimicrobial Neuropeptides

### **4. PORTRAYAL OF PEPTIDE ANTIBIOTICS IN CANCER TREATMENT**

- 4.1 Introduction
- 4.2 Mechanism of Antimicrobial Peptides in Cancer Treatment

### **5. CATEGORIZATION OF ANTICANCER PEPTIDES**

- 5.1 Alpha-Helical Anticancer Peptides
- 5.2 Beta-Sheet Anticancer Peptides

### **6. APPROVED PEPTIDE ANTIBIOTICS**

- 6.1 Bacitracin
- 6.2 Viomycin

### **7. MARKET ANALYSIS OF PEPTIDE ANTIBIOTICS**

- 7.1 Introduction to Antibacterial Drug Market
- 7.2 Global Antimicrobial Peptide Market

## **8. MARKET DYNAMICS OF ANTIMICROBIAL PEPTIDES**

8.1 Favorable Parameters

8.2 Challenges

## **9. FUTURE PERSPECTIVE OF PEPTIDE ANTIBIOTICS MARKET & DRUG DEVELOPMENT**

## **10. GLOBAL PEPTIDE ANTIBIOTICS CLINICAL PIPELINE OVERVIEW**

10.1 By Country

10.2 By Indication

10.3 By Mode of Action

10.4 By Formulation

10.5 By Delivery Route

## **11. GLOBAL PEPTIDE ANTIBIOTICS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

11.1 Research

11.2 Preclinical

11.3 Clinical

11.4 Phase-I

11.5 Phase-II

11.6 Phase-III

11.7 Preregistration

## **12. MARKETED PEPTIDE ANTIBIOTICS CLINICAL & PATENT ANALYSIS**

12.1 Telavancin (Arbelic & Vibativ)

12.2 Dalbavancin (Dalvance & Xydalba)

12.3 Daptomycin Intravenous (Cubicin)

12.4 Oritavancin (Nuvocid & ORBACTIV)

12.5 Teicoplanin (Targocid)

12.6 Vancomycin (Vancomycin hydrochloride)

## **13. COMPETITIVE LANDSCAPE**

- 13.1 AMP Therapeutics
- 13.2 Eli Lilly
- 13.3 GlaxoSmithKline
- 13.4 Hospira
- 13.5 Kasten
- 13.6 Madam Therapeutics
- 13.7 Novartis
- 13.8 Pacgen Life Science Corporation
- 13.9 Pfizer
- 13.10 Phosphagenics
- 13.11 Savara Pharmaceuticals
- 13.12 Theravance
- 13.13 Vicuron Pharmaceuticals

## List Of Figures

### LIST OF FIGURES

Figure 1-1: Structure of Some Important Peptide Antibiotics

Figure 1-2: Classification & Characterization of Peptide Antibiotics

Figure 2-1: Targets for Antimicrobial Peptides to Inhibit the Bacterial Growth

Figure 2-2: Chemical Structure of Teixobactin

Figure 2-3: Steps for the Solid Phase Synthesis of Teixobactin

Figure 3-1: Typical Processing of Cathelicidin Protein by Protease Enzymes

Figure 3-2: Mechanism of Antimicrobial Peptides in Defense against Pathogens

Figure 4-1: Angiogenesis Inhibition Mechanism of Action

Figure 6-1: Bacitracin - Mechanism of Action

Figure 7-1: Global - Antibacterial Drug Market (US\$ Billion), 2016-2023

Figure 7-2: Usage of Therapeutic Peptides & Proteins in Different Disorders (%)

Figure 7-3: Global - Peptide Drug Market (US\$ Billion), 2016-2023

Figure 7-4: Therapeutic Peptide Based Drugs over Route of Administration

Figure 7-5: Global - Peptide Antibiotics Clinical Pipeline by Phase (%), 2017 till 2023

Figure 7-6: Global - Peptide Antibiotics Clinical Pipeline by Phase (Number), 2017 till 2023

Figure 8-1: Favorable Parameters which Helps in the Growth of Antimicrobial Peptide

Figure 8-2: Challenges to Antimicrobial Peptide Market Growth

Figure 9-1: Different Possible Treatment Options of Cancer by Using Peptides

Figure 10-1: Global - Peptide Antibiotics Clinical Pipeline by Country (%), 2017 till 2023

Figure 10-2: Global - Peptide Antibiotics Clinical Pipeline by Indication (%), 2017 till 2023

Figure 10-3: Global - Peptide Antibiotics Clinical Pipeline by Mode of Action (%), 2017 till 2023

Figure 10-4: Global - Peptide Antibiotics Clinical Pipeline by Formulation (%), 2017 till 2023

Figure 10-5: Global - Peptide Antibiotics Clinical Pipeline by Delivery Route (%), 2017 till 2023

## List Of Tables

### LIST OF TABLES

Table 3-1: Cell Sources of Human Defensins Antimicrobial Peptides

Table 9-1: Future Human Antimicrobial Peptides and their Proposed Targets

### COMPANIES MENTIONED

AMP Therapeutics,  
Eli Lilly,  
GlaxoSmithKline,  
Hospira,  
Kasten,  
Madam Therapeutics,  
Novartis,  
Pacgen Life Science Corporation,  
Pfizer,  
Phosphagenics,  
Savara Pharmaceuticals,  
Theravance,  
Vicuron Pharmaceuticals

## I would like to order

Product name: Global Peptide Antibiotics Market & Clinical Pipeline Insight 2023

Product link: <https://marketpublishers.com/r/G1C50B297D1EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1C50B297D1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970